Abraxis BioScience, Inc. (ABII) Tops Taxol in Cancer Study

In the company’s news yesterday,

Abraxis BioScience Inc. announced that its chemotherapeutic compound ABRAXANE® has demonstrated a significant improvement in overall response rate in the treatment of the most common form of lung cancer when compared to Taxol®, based upon independent radiologist review.

The study was a randomized registrational Phase 3 clinical trial comparing ABRAXANE (protein-bound paclitaxel) with Taxol (paclitaxel) injection, both in combination with carboplatin, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). One of the largest NSCLC clinical studies ever conducted, it involved over 1,000 patients, at 102 different sites around the world.

Mark Socinski, M.D., of the University of North Carolina Lineberger Comprehensive Cancer Center, the principal investigator, said of the study, “This is exciting news for lung cancer patients and has important implications not only in late stage cancer but also in earlier stages of the disease. The data will be submitted for consideration as a late breaking presentation at the upcoming American Society of Clinical Oncology (ASCO) meeting”.

Patrick Soon-Shiong, M.D., Executive Chairman and founder of Abraxis BioScience, added, “NSCLC is the most common form of lung cancer and is very difficult to treat. We are extremely pleased with the data from this Phase 3 combination study that demonstrated superiority of ABRAXANE over Taxol as we seek to bring new treatment options to these patients. We anticipate filing an sNDA (supplemental new drug application) to the FDA during 2011 for what will be the second indication for ABRAXANE in the U.S.”

NSCLC accounts for approximately 85% of all lung cancer cases, resulting in roughly 159,000 U.S. deaths annually. The American Cancer Society estimates that over 219,000 people were diagnosed with lung cancer in 2009. ABRAXANE is now in various stages of investigation for the treatment of other cancers as well, including expanded applications for metastatic breast cancer, malignant melanoma, pancreatic and gastic cancers. ABRAXANE, which is based on the company’s proprietary tumor targeting technology known as the nab® platform, has already been approved in 39 countries for the treatment of metastatic breast cancer.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.